XW 10508
Alternative Names: XW 10508Latest Information Update: 28 Aug 2024
At a glance
- Originator XW labs
- Developer XWPharma
- Class Analgesics; Antidepressants; Small molecules
- Mechanism of Action AMPA receptor agonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder; Pain
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Australia (PO, Controlled release)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Australia (PO, Immediate release)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Pain(In volunteers) in Australia (PO, Controlled release)